secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tevogen Bio Holdings Inc. (TVGN)
CIK:        0001860871
Form:       8-K
Filed at:   2023-09-14T23:59:59+00:00
Accession:  0001493152-23-032672
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Semper Paratus files S-4 for merger with Tevogen Bio; expects close near end of 2023
--------------------------------------------------------------------------------

- Filed Registration Statement on Form S-4 with SEC for proposed business combination with Tevogen Bio.
- Combined company to be named Tevogen Bio Holdings Inc., expected to trade on NYSE American as TVGN/TVGNW.
- Transaction approved by both boards; closing subject to SEC review, shareholder approval, and other conditions.
- Tevogen Bio is a clinical-stage immunotherapy company developing off-the-shelf T cell therapies in virology, oncology, neurology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860871/000149315223032672/0001493152-23-032672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860871/000149315223032672/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-032672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer